Etoposide
- Generic Name
- Etoposide
- Brand Names
- Etopophos, Toposar, Vepesid
- Drug Type
- Small Molecule
- Chemical Formula
- C29H32O13
- CAS Number
- 33419-42-0
- Unique Ingredient Identifier
- 6PLQ3CP4P3
- Background
A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to ce...
- Indication
For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
- Associated Therapies
- -
Phase 1b/2 Study of LDRT in Combination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLC
- Conditions
- Interventions
- First Posted Date
- 2024-06-27
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Sichuan University
- Target Recruit Count
- 57
- Registration Number
- NCT06477523
- Locations
- 🇨🇳
China West Hospital, Chengdu, Sichuan, China
🇨🇳West China Hospital, Sichuan University, Chengdu, Sichuan, China
A Study of Adebrelimab Combined With Chemoradiotherapy in the Treatment of Esophageal Small Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-06-27
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Zhangzhou Municipal Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT06478264
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
- First Posted Date
- 2024-06-07
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 110
- Registration Number
- NCT06449209
- Locations
- 🇺🇸
Hematology Oncology Associates of Treasure Coast, Port Saint Lucie, Florida, United States
🇺🇸Tallahassee Memorial Physician Partners - Cancer & Hematology Specialists, Tallahassee, Florida, United States
🇺🇸Carle Foundation Hospital d/b/a Carle Cancer Center, Urbana, Illinois, United States
Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis
- Conditions
- Interventions
- First Posted Date
- 2024-05-17
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Beijing 302 Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06418594
- Locations
- 🇨🇳
The Fifth Medical Center of PLA General Hospital, Beijing, Beijing, China
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
- Conditions
- Interventions
- First Posted Date
- 2024-05-09
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT06406465
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
- Conditions
- Interventions
- Procedure: NephrectomyProcedure: Computed TomographyProcedure: Bone ScanDrug: CarboplatinBiological: DactinomycinOther: Patient ObservationProcedure: Magnetic Resonance ImagingDrug: DoxorubicinDrug: CyclophosphamideProcedure: Ultrasound ImagingDrug: VincristineDrug: EtoposideProcedure: X-Ray ImagingDrug: IrinotecanProcedure: Positron Emission Tomography
- First Posted Date
- 2024-05-06
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 1656
- Registration Number
- NCT06401330
MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-04-22
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 28
- Registration Number
- NCT06377540
Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.
- Conditions
- Interventions
- First Posted Date
- 2024-04-18
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 93
- Registration Number
- NCT06372626
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, Beijing, China
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma
- Conditions
- Interventions
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 240
- Registration Number
- NCT06368817
- Locations
- 🇺🇸
Loma Linda University Medical Center, Loma Linda, California, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States
GAMEC-II, Risk-adapted Protocol for Relapsed Germ Cell Tumours (GCT)
- Conditions
- Interventions
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Queen Mary University of London
- Target Recruit Count
- 36
- Registration Number
- NCT06309732
- Locations
- 🇬🇧
Barts and the London NHS Trust, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.